Sharon Hausman-Cohen M.D., FAAFP, ABIHM

Dr. Sharon Hausman-Cohen is the Chief Medical Officer and co-founder of IntellxxDNA and of a precision medicine practice, Resilient Health Austin. Dr. Hausman-Cohen received both her master’s degree and medical degree from Harvard Medical School. She is a fellow of the American Academy of Family Medicine and a diplomate of the American Board of Integrative Medicine. Dr. Hausman-Cohen has been in the field of integrative medicine for over 25 years. She and her co-founder developed IntellxxDNA as an answer to an unmet need in the integrative and functional medicine community; the need for an accurate, evidence-based genomics tool geared at helping functional and integrative physicians practice personalized medicine. They envisioned and created a tool that could help identify root causes of cognitive decline, environmentally acquired illness, autism, and other chronic illnesses, and one that could also help clinicians know how to address these genomic factors. The IntellxxDNA™ clinical decision support tool is now being used to make genomics actionable and understandable and is being used as part of medical decision-making by Integrative and Functional Medicine physicians across the country. Dr. Hausman-Cohen loves combining her passion for science and medicine and using her scientific mind to integrate large amounts of complex data. She has taught extensively across the country at conferences for physicians as well as for community members and will be featured in a documentary being released in 2022 on the “Future of Healthcare”. She is also writing a precision medicine textbook chapter on “Genomics for improving precision medicine outcomes”. The genomics developed by Dr. Hausman-Cohen and her team are being used for research and to improve outcomes for individuals in private physicians’ offices across the world. Recent paper with Dr. Heather Way in the Journal of Personalized Medicine focused on outcomes in children with ASD. She is also a co-author on a cognition study publication with Dr. Dale Bredesen, and has two other publications pending regarding improving outcomes in cognition and autism. She has additionally published review papers discussing Alzheimer’s disease and neurocognition genomics as well as a paper on the Genomics of Detoxification: “How Genomics can be Used for Targeting Potential Intervention and Prevention Strategies for Environmentally Acquired Illness”. She was also one of the co-authors along with Dr. Dale Bredesen on his landmark paper, “Reversal of Cognitive Decline: 100 patients”.